Beal will succeed Lynn Elsenhans as chair of GSK’s corporate responsibility committee following the 2022 AGM.
Dr Anne Beal has joined the board of GlaxoSmithKline as a non-executive director.
She has been appointed to the GSK corporate responsibility committee and will succeed Lynn Elsenhans as chair of the committee following the 2022 AGM. Elsenhans has agreed to remain on the board for a further year to facilitate a smooth transition.
Beal is founder and CEO of AbsoluteJOI Skincare and a member of the board of AcademyHealth. She spent six years at Harvard Medical School and Massachusetts General Hospital, where she was an instructor in paediatrics, and has also held leadership roles at the Commonwealth Fund and the Aetna Foundation.
For thoughtful journalism, expert insights on corporate governance and an extensive library of reports, guides and tools to help boards and directors navigate the complexities of their roles, subscribe to Board Agenda